TALOPH(SH:600222)2018-10-26 16:00Financial Performance - Operating revenue for the year-to-date was approximately CNY 850.09 million, representing a year-on-year increase of 6.67%[6] - Net profit attributable to shareholders was approximately CNY 5.65 million, an increase of 102.31% compared to the same period last year[6] - Basic earnings per share increased by 100% to CNY 0.0098 from CNY 0.0049 in the same period last year[6] - The company reported a significant increase in net profit after deducting non-recurring gains and losses, which was approximately CNY 1.12 million, up 17.38% year-on-year[6] - The company reported a total comprehensive income of ¥2,857,712.70 for Q3 2018, compared to ¥207,658.49 in Q3 2017[30] - Net profit for Q3 2018 was ¥2,857,712.70, compared to ¥207,658.49 in Q3 2017, indicating a significant increase[29] - Net profit for Q3 was ¥13,355,893.89, a decrease of 10.2% from ¥14,878,636.23 year-over-year[32] - The company reported a total profit of ¥12,183,440.49 for Q3, slightly down from ¥12,298,958.23 in the previous year[32] Cash Flow - Cash flow from operating activities showed a significant improvement, with a net amount of approximately CNY 39.11 million, compared to a negative CNY 6.70 million in the previous year[6] - The company reported a net cash flow from operating activities of ¥39,107,462.24, a substantial increase compared to a net outflow of ¥6,704,878.60 in the previous year[14] - Operating cash inflow for the year-to-date period reached ¥223,014,016.86, a significant increase of 59.2% compared to ¥140,034,854.56 in the same period last year[39] - Net cash flow from operating activities was negative at -¥20,249,893.10, an improvement from -¥38,871,480.99 year-over-year[40] - Cash flow from financing activities showed a net outflow of -¥89,622,739.38, a decline from a net inflow of ¥8,905,538.81 in the same period last year[40] Assets and Liabilities - Total assets at the end of the reporting period were approximately CNY 2.72 billion, a decrease of 3.24% compared to the end of the previous year[6] - The total number of shareholders at the end of the reporting period was 46,003[10] - The company maintained a stable net asset attributable to shareholders at approximately CNY 1.49 billion, with a slight increase of 0.02% compared to the previous year[6] - Total current assets decreased from CNY 1,582,083,933.48 at the beginning of the year to CNY 1,513,400,565.99 by September 30, 2018, a decline of approximately 4.36%[19] - Total liabilities decreased significantly, with a notable reduction in minority interests by 86.42% to ¥2,505,559.68 due to the transfer of equity stakes in Tai Xin Long and Hebei Tai Long[13] - Total liabilities decreased from CNY 1,299,932,235.12 to CNY 1,224,473,687.29, a decline of about 5.79%[21] Research and Development - Research and development expenses increased by 48.14% to ¥49,341,350.75, primarily due to the termination of the research on the product "Creeping Blood Circulation Soft Capsule"[14] - Research and development expenses for Q3 2018 were ¥24,668,100.15, an increase of 55.5% compared to ¥15,882,403.91 in Q3 2017[28] - The company decided to terminate the research and development of the "Creeping Blood Circulation Soft Capsule," resulting in a reduction of net profit by ¥15,230,800 after tax effects[14] - Research and development expenses surged to ¥21,870,009.18, up 103.1% from ¥10,762,676.12 in the previous year[31] Government Support - Government subsidies received during the reporting period amounted to approximately CNY 1.97 million, contributing positively to the financial results[9] - Other income rose by 152.95% to ¥5,831,319.92, mainly due to increased government subsidies related to daily activities compared to the previous year[14] Market and Future Plans - The company has indicated plans for market expansion and new product development in the upcoming quarters[27]